Cytoprotective Effects of Amifostine in the Treatment of Childhood Malignancies

Basit Öğe Kaydı
dc.contributor.authorCetinguel, Nazan
dc.contributor.authorMidyat, Levent
dc.contributor.authorKantar, Mehmet
dc.contributor.authorDemirag, Bengue
dc.contributor.authorAksoylar, Serap
dc.contributor.authorKansoy, Savas
dc.date.accessioned2019-10-27T20:51:00Z
dc.date.available2019-10-27T20:51:00Z
dc.date.issued2009
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground. Multi-systemic acute side effects occur, in response to intensive therapies that have been applied in childhood malignancies in recent years. Amifostine has rarely been used in the childhood cancers as a multisystemic protective agent for minimizing these side effects. Procedure. In this Study, the effectiveness of amifostine in combination with chemotherapy for childhood cancer treatment has been researched. Of 11 Subjects (2.5 months-17 years) 4 Subjects had leukemia, 4 had solid tumor, and 3 1 ad lymphoma. For these 11 subjects, 29 chemotherapy Courses were given in combination with amifostine, and 20 without amifostine. Their hematological, gastrointestinal and hepatic toxicity were evaluated according to the WHO toxicity criteria. Amifostine was given intravenously in a dose of 740 mg/m(2), one to three consecutive days depending on the chemotherapy regimen. Results. The hemoglobin, leukocyte, and platelet levels of the two groups were not statistically different. However, when comparing the Courses of the patients receiving the same medications at the same closes, in the group with amifostine, mean erythrocyte transfusion requirement was significantly reduced (P=0.025). In 31%, of the Courses with amifostine and 50% of the Courses Without amifostine, febrile neutropenia developed. Gastrointestinal system and hepatic toxicity Was Significantly reduced in the Courses with amifostine with respect to those without it (P=0.001). Vomiting, hypotension and nausea were the only side effects related to amifostine. Conclusion. Use of amifostine during the treatment of childhood cancers with intensive chemotherapy and/or radiotherapy significantly reduced the erythrocyte transfusion requirements of the patients as well as gastrointestinal and hepatic toxicity. Pediatr Blood Cancel 2009;52:829-833. (C) 2009 Wiley-Liss, Inc.en_US
dc.identifier.doi10.1002/pbc.21959en_US
dc.identifier.endpage833en_US
dc.identifier.issn1545-5009
dc.identifier.issn1545-5017
dc.identifier.issue7en_US
dc.identifier.pmid19214974en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage829en_US
dc.identifier.urihttps://doi.org/10.1002/pbc.21959
dc.identifier.urihttps://hdl.handle.net/11454/43062
dc.identifier.volume52en_US
dc.identifier.wosWOS:000265346100017en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatric Blood & Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectamifostineen_US
dc.subjectchemoprotectanten_US
dc.subjectchemotherapyen_US
dc.subjectpediatric cancersen_US
dc.titleCytoprotective Effects of Amifostine in the Treatment of Childhood Malignanciesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu